Skip to main content
OpenTrials
Completed

NCT Number: NCT03893162

Gut Feeling: Understanding the Mechanisms Underlying the Antidepressant Properties of Probiotics

Previous research has suggested that probiotics can improve depressive symptoms in patients with Major Depressive Disorder (MDD), particularly when used in addition to antidepressants. The aim of this exploratory pilot study is to improve the investigator's understanding of the mechanisms underlying these effects. This study will assess the effects of an 8-week double-blind placebo-controlled probiotic intervention on the gut microbiome, inflammatory marker levels, brain activity and neurotransmitter levels in patients with MDD and their relationship to changes in mood. This study will also recruit a group of demographically-matched healthy controls for gut microbiome comparison with the MDD group (non-interventional).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King's College London

London, SE5 8AF, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for MDD participants:

  • aged 18-55;
  • currently in a depressive episode according to DSM-5 criteria, who are currently on antidepressant treatment but remain symptomatic (HAM-D17 score >13);
  • on stable treatment regimen of an approved treatment for at least 6 weeks;
  • non-smokers;
  • for participants willing to take part in the neuroimaging component: right-handed, no contraindications, non-claustrophobic, weight <126kg;

Exclusion criteria

for MDD participants:

  • eating disorder, bipolar disorder, schizophrenia or psychotic symptoms;
  • substance dependence in the past year, except for caffeine;
  • active suicidal ideation;
  • use of probiotic supplements in the past 2 weeks, or regular use of a probiotic;
  • use of antibiotics in the past 12 weeks;
  • history of allergic reaction to any of the components of BioKult;
  • history of history of a systemic medical illness;
  • current presence of significant GI problems or disease or history of major GI surgery;
  • pregnancy or breastfeeding;
  • following a dietary regimen unrepresentative of the general population (e.g. fasting or following a specific diet);
  • regular/current use of antacids, proton pump inhibitors, laxatives, antidiarrheals;

Inclusion criteria

for Healthy Volunteers:

  • Aged 18-55;
  • No current or historic presence of depression, other psychiatric disorder or substance dependence
  • No history of a systemic medical illness;
  • No family history of psychiatric disorder;
  • Non-smoker;
  • Not used probiotic supplements in the past 2 weeks, nor regular use of a probiotic;
  • Not used antibiotics in the past 12 weeks;
  • No current presence of gastrointestinal disease, or history of major GI surgery;
  • No reported regular/current use of antacids, proton pump inhibitors, laxatives, antidiarrheals;
  • pregnancy or breastfeeding;
  • not currently following a dietary regimen or dietary restrictions unrepresentative of the general population (e.g. fasting or following a specific diet);

Treatment and study plan

Multi-strain probiotic

Dietary Supplement

The intervention in this study is a multi-strain probiotic which contains:

Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.

Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram.

Other names: "BioKult"

Placebo

Other

Visually identical capsules in identical packaging containing no active bacteria.

Primary outcomes

  1. gut microbiota in MDD

    Time frame: baseline

    species diversity and abundance at the level of organisational taxonomic units (OTUs) will be measured with 16S ribosomal RNA (rRNA) sequencing

  2. differences in gut microbiota between MDD and healthy volunteers

    Time frame: baseline

    species diversity and abundance at the level of OTUs will be measured with 16SrRNA-based sequencing and compared between the two groups

  3. gut microbiota changes in MDD following probiotic intervention and their correlation to change in depressive symptoms

    Time frame: change from baseline to week 8

    species diversity and abundance at the level of OTUs will be measured with 16SrRNA-based sequencing and depressive symptoms will be measured with the Inventory of Depressive Symptomatology Self-Report (IDS-SR) and the Hamilton Depression Rating Scale (HAM-D17)

Secondary outcomes

  1. Neurotransmitters

    Time frame: change from baseline to week 8

    levels of glutamate and gamma-aminobutyric acid (GABA) will be measured with Magnetic Resonance Imaging (MRS)

  2. Blood

    Time frame: change from baseline to week 8

    levels of tumor necrosis factor (TNF-a), interleukins IL-1β, IL-6, IL-17, and C-reactive protein (CRP) will be measured

  3. Brain activity

    Time frame: change from baseline to week 8

    measured with functional magnetic resonance imaging (fMRI)

Sponsors and collaborators

Lead sponsor

King's College London

Other

Registry information

Acronym: PROMEX

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Mar 28, 2019
Registry last updated
Jun 30, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.